Latest News

Galux and ISU Abxis Sign MOU to Collaborate on AI-Driven Drug Discovery
Read More
Galux and Woojung Bio Forge Strategic Partnership to Accelerate AI-Driven Therapeutics Development
Read More
Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets
Read More
Designed by AI: the future of antibody drugs
Read More
Galux and HanAll Biopharma Initiate Strategic Collaboration to Develop AI-Designed Antibody Therapeutics for Cancer
Read More
Pioneering Precision: How South Korea's Galux is Redefining Antibody Discovery with AI
Read More
[Interview] DeepMind predicted proteins. A Korean startup says it's designing the future of antibodies.
Read More
Korean AI firm Galux develops six novel therapeutic antibodies using innovative design methods
Read More
Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets
Read More
Galux Unveils Breakthrough AI Technology for Therapeutic Antibody Loop Design
Read More
Galux to conduct joint research with LG Chem on cancer drug development
Read More
Galux and LG Chem Initiate Joint Research on AI-Powered Cancer Drug Development
Read More